Ascendis Pharma AS
A71
Company Profile
Business description
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology, which includes TransCon PTH, TransCon CNP, and others. It operates in the United States, Europe, and the rest of the world and derives the majority of its revenue from the United States.
Contact
Tuborg Boulevard 12
Hellerup2900
DNKT: +45 70222244
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,189
Stocks News & Analysis
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
stocks
The SpaceX IPO and the Elon Musk factor
Potential investors should remember that the company’s controlling shareholder can move markets with a few words.
stocks
The ASX’s most shorted stocks in 2026
What we can and can’t learn from the top 20 most shorted ASX shares.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,632.50 | 39.90 | -0.46% |
| CAC 40 | 7,772.45 | 70.50 | 0.92% |
| DAX 40 | 22,562.88 | 262.13 | 1.18% |
| Dow JONES (US) | 45,216.14 | 49.50 | 0.11% |
| FTSE 100 | 10,127.96 | 160.61 | 1.61% |
| HKSE | 24,750.79 | 201.09 | -0.81% |
| NASDAQ | 20,794.64 | 153.72 | -0.73% |
| Nikkei 225 | 50,676.59 | 1,209.26 | -2.33% |
| NZX 50 Index | 12,732.99 | 15.93 | -0.12% |
| S&P 500 | 6,343.72 | 25.13 | -0.39% |
| S&P/ASX 200 | 8,438.80 | 38.40 | -0.45% |
| SSE Composite Index | 3,923.29 | 9.56 | 0.24% |